> top > docs > PubMed:24603724 > annotations

PubMed:24603724 JSONTXT

Annnotations TAB JSON ListView MergeView

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 147-325 DRI_Approach denotes Neuroblastoma (NB) is the most common extra-cranial pediatric solid tumor with up to 50% of NB patients classified as having high-risk disease with poor long-term survival rates.
T2 326-536 DRI_Outcome denotes The poor clinical outcome and aggressiveness of high-risk NB strongly correlates with enhanced angiogenesis, suggesting anti-angiogenic agents as attractive additions to the currently insufficient therapeutics.
T3 537-628 DRI_Background denotes TL-118, a novel drug combination has been recently developed to inhibit tumor angiogenesis.
T4 629-857 DRI_Approach denotes In the current study, we used the SK-N-BE (2) cell line to generate orthotopic NB tumors in order to study the combinational therapeutic potential of TL-118 with either Gemcitabine (40 mg/kg; IP) or Retinoic acid (40 mg/kg; IP).
T5 858-1010 DRI_Outcome denotes We show that TL-118 treatment (n = 9) significantly inhibited tumor growth, increased cell apoptosis, reduced proliferation and extended mouse survival.
T6 1011-1130 DRI_Approach denotes Moreover, the reciprocal effect of TL-118 and Gemcitabine treatment (n = 10) demonstrated improved anti-tumor activity.
T7 1131-1390 DRI_Approach denotes The synergistic effect of these drugs in combination was more effective than either TL or Gemcitabine alone (n = 9), via significantly reduced cell proliferation (p<0.005), increased apoptosis (p<0.05) and significantly prolonged survival (2-fold; p<0.00001).
T8 1391-1523 DRI_Challenge denotes To conclude, we demonstrate that the novel drug combination TL-118 has the ability to suppress the growth of an aggressive NB tumor.
T9 1524-1677 DRI_Outcome denotes The promising results with TL-118 in this aggressive animal model may imply that this drug combination has therapeutic potential in the clinical setting.

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-146 Sentence denotes TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI.
TextSentencer_T2 147-325 Sentence denotes Neuroblastoma (NB) is the most common extra-cranial pediatric solid tumor with up to 50% of NB patients classified as having high-risk disease with poor long-term survival rates.
TextSentencer_T3 326-536 Sentence denotes The poor clinical outcome and aggressiveness of high-risk NB strongly correlates with enhanced angiogenesis, suggesting anti-angiogenic agents as attractive additions to the currently insufficient therapeutics.
TextSentencer_T4 537-628 Sentence denotes TL-118, a novel drug combination has been recently developed to inhibit tumor angiogenesis.
TextSentencer_T5 629-857 Sentence denotes In the current study, we used the SK-N-BE (2) cell line to generate orthotopic NB tumors in order to study the combinational therapeutic potential of TL-118 with either Gemcitabine (40 mg/kg; IP) or Retinoic acid (40 mg/kg; IP).
TextSentencer_T6 858-1010 Sentence denotes We show that TL-118 treatment (n = 9) significantly inhibited tumor growth, increased cell apoptosis, reduced proliferation and extended mouse survival.
TextSentencer_T7 1011-1130 Sentence denotes Moreover, the reciprocal effect of TL-118 and Gemcitabine treatment (n = 10) demonstrated improved anti-tumor activity.
TextSentencer_T8 1131-1390 Sentence denotes The synergistic effect of these drugs in combination was more effective than either TL or Gemcitabine alone (n = 9), via significantly reduced cell proliferation (p<0.005), increased apoptosis (p<0.05) and significantly prolonged survival (2-fold; p<0.00001).
TextSentencer_T9 1391-1523 Sentence denotes To conclude, we demonstrate that the novel drug combination TL-118 has the ability to suppress the growth of an aggressive NB tumor.
TextSentencer_T10 1524-1677 Sentence denotes The promising results with TL-118 in this aggressive animal model may imply that this drug combination has therapeutic potential in the clinical setting.
T1 0-146 Sentence denotes TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI.
T2 147-325 Sentence denotes Neuroblastoma (NB) is the most common extra-cranial pediatric solid tumor with up to 50% of NB patients classified as having high-risk disease with poor long-term survival rates.
T3 326-536 Sentence denotes The poor clinical outcome and aggressiveness of high-risk NB strongly correlates with enhanced angiogenesis, suggesting anti-angiogenic agents as attractive additions to the currently insufficient therapeutics.
T4 537-628 Sentence denotes TL-118, a novel drug combination has been recently developed to inhibit tumor angiogenesis.
T5 629-857 Sentence denotes In the current study, we used the SK-N-BE (2) cell line to generate orthotopic NB tumors in order to study the combinational therapeutic potential of TL-118 with either Gemcitabine (40 mg/kg; IP) or Retinoic acid (40 mg/kg; IP).
T6 858-1010 Sentence denotes We show that TL-118 treatment (n = 9) significantly inhibited tumor growth, increased cell apoptosis, reduced proliferation and extended mouse survival.
T7 1011-1130 Sentence denotes Moreover, the reciprocal effect of TL-118 and Gemcitabine treatment (n = 10) demonstrated improved anti-tumor activity.
T8 1131-1390 Sentence denotes The synergistic effect of these drugs in combination was more effective than either TL or Gemcitabine alone (n = 9), via significantly reduced cell proliferation (p<0.005), increased apoptosis (p<0.05) and significantly prolonged survival (2-fold; p<0.00001).
T9 1391-1523 Sentence denotes To conclude, we demonstrate that the novel drug combination TL-118 has the ability to suppress the growth of an aggressive NB tumor.
T10 1524-1677 Sentence denotes The promising results with TL-118 in this aggressive animal model may imply that this drug combination has therapeutic potential in the clinical setting.

DisGeNET

Id Subject Object Predicate Lexical cue
T0 74-78 gene:4613 denotes MYCN
T1 100-113 disease:C0027819 denotes neuroblastoma
T2 74-78 gene:4613 denotes MYCN
T3 100-113 disease:C0700095 denotes neuroblastoma
R1 T0 T1 associated_with MYCN,neuroblastoma
R2 T2 T3 associated_with MYCN,neuroblastoma

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 147-160 HP_0003006 denotes Neuroblastoma
T2 215-220 HP_0002664 denotes tumor
T3 356-370 HP_0000718 denotes aggressiveness
T4 609-614 HP_0002664 denotes tumor
T5 711-717 HP_0002664 denotes tumors
T6 920-925 HP_0002664 denotes tumor
T7 1115-1120 HP_0002664 denotes tumor
T8 1503-1513 HP_0000718 denotes aggressive
T9 1517-1522 HP_0002664 denotes tumor
T10 1566-1576 HP_0000718 denotes aggressive

Allie

Id Subject Object Predicate Lexical cue
SS1_24603724_1_0 147-160 expanded denotes Neuroblastoma
SS2_24603724_1_0 162-164 abbr denotes NB
AE1_24603724_1_0 SS1_24603724_1_0 SS2_24603724_1_0 abbreviatedTo Neuroblastoma,NB

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
24603724-0#74#78#gene4613 74-78 gene4613 denotes MYCN
24603724-0#100#113#diseaseC0027819 100-113 diseaseC0027819 denotes neuroblastoma
24603724-0#100#113#diseaseC0700095 100-113 diseaseC0700095 denotes neuroblastoma
74#78#gene4613100#113#diseaseC0027819 24603724-0#74#78#gene4613 24603724-0#100#113#diseaseC0027819 associated_with MYCN,neuroblastoma
74#78#gene4613100#113#diseaseC0700095 24603724-0#74#78#gene4613 24603724-0#100#113#diseaseC0700095 associated_with MYCN,neuroblastoma

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T40 74-78 gene:4613 denotes MYCN
T41 100-113 disease:C0027819 denotes neuroblastoma
R1 T40 T41 associated_with MYCN,neuroblastoma
R2 T40 T41 associated_with MYCN,neuroblastoma